Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) is expected to be posting its quarterly earnings results before the market opens on Thursday, March 13th. Analysts expect Monte Rosa Therapeutics to post earnings of ($0.27) per share for the quarter.
Monte Rosa Therapeutics Trading Up 1.6 %
Shares of GLUE traded up $0.10 during mid-day trading on Friday, hitting $6.39. 815,647 shares of the company's stock were exchanged, compared to its average volume of 699,210. Monte Rosa Therapeutics has a fifty-two week low of $3.21 and a fifty-two week high of $12.40. The firm has a market capitalization of $392.58 million, a P/E ratio of -3.49 and a beta of 1.50. The business's 50 day moving average is $6.22 and its two-hundred day moving average is $6.77.
Wall Street Analysts Forecast Growth
Separately, Wells Fargo & Company downgraded shares of Monte Rosa Therapeutics from an "overweight" rating to an "equal weight" rating and decreased their target price for the stock from $14.00 to $11.00 in a research note on Thursday, December 19th.
View Our Latest Stock Analysis on Monte Rosa Therapeutics
Monte Rosa Therapeutics Company Profile
(
Get Free Report)
Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.
See Also
Before you consider Monte Rosa Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monte Rosa Therapeutics wasn't on the list.
While Monte Rosa Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
